Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Toxicol Res
2010 Mar 01;261:37-46. doi: 10.5487/tr.2010.26.1.037.
Show Gene links
Show Anatomy links
Methanolic Extract of Asterina pectinifera inhibits LPS-Induced Inflammatory Mediators in Murine Macrophage.
Jo WS
,
Choi YJ
,
Kim HJ
,
Nam BH
,
Lee GA
,
Seo SY
,
Lee SW
,
Jeong MH
.
???displayArticle.abstract???
This study aimed to elucidate anti-inflammatory activities from extracts of Asterina pectinifera on nitric oxide (NO) production, TNF-α and IL-6 release in lipopolysaccharide (LPS) -stimulated murine macrophage cell, RAW264.7. We prepared the methanolic extracts (60-MAP, 70-MAP, 80-MAP and 90-MAP) , aqueous extract (W-AP) and functional bioactive compound fraction (He-AP and EA-AP) from Asterina pectinifera according to extract method. The 60-MAP, 70-MAP, 80-MAP, 90-MAP and W-AP were significantly suppressed LPS-induced production NO, TNF-α and IL-6 secretion in a concentration-dependent manner (P < 0.05) . Especially, 80-MAP by extracted 80% methanol had the strongest activity in reduction of inflammatory mediators among these extracts. Indeed, to identify active fraction, which contained potential bioactive compounds, from 80-MAP of Asterina pectinifera, we tested anti-inflammatory activity of the He-AP or the EA-AP. The He-AP was next extracted from 80-MAP and the EA-AP were extracted from the other methanol layer except the He-AP. The EA-AP demonstrated a strong anti-inflammatory effect through its ability to reduce NO production and it also inhibited the production of proinflammatory cytokines such as IL-6 and TNF-α at low concentration. These results suggested that the methanolic extract from Asterina pectinifera had the potential inhibitory effects on the production of these inflammatory mediators.
Fig. 1. Procedure for extraction or fraction of bioactive compounds from Asterina pectinifera. The extractive procedures were described in (A) the methnolic extraction, (B) the aqueous extraction and (C) the hexane fraction or ethyl acetate fraction according to extract method from Asterina pectinifera.
Fig. 2. Cytotoxicity of extracts from Asterina pectinifera in RAW 264.7 cell. RAW 264.7 cells were treated with each concentration of the methnolic extracts (60-MAP 70-MAP 80-MAP and 90-MAP) and aqueous extract (W-AP) from Asterina pectinifera (A) , hexane fraction (He-AP) and ethyl acetate fraction (EA-AP) (B) for 24 h. Cell viability was determined by MTT assay. Three independent assays were performed in triplicate and the data shown are the mean ± SD.
Fig. 3. Effects of the methanolic and aqueous extract from Asterina pectinifera on LPS-induced nitirc oxide (NO) in murine macrophages. RAW 264.7 cells were treated with concentrations of methanolic and aqueous extract from Asterina pectinifera (60-MAP 70-MAP 80-MAP 90-MAP and W-AP) in the presence of 500 ng/ml of LPS or LPS alone for 24 h. L-NMMA was used as a positive control. Three independent assays were performed in triplicate and the data shown are the mean ± S.D. *P < 0.05 vs. media alone and #P < 0.05 vs. LPS-treated group (control) ; significance of difference between treated groups by Students-t tests (*) and ANOVA followed by Dunnett’s test (#) .
Fig. 6. Effects by active compound fraction from 80-MAP of Asterina pectinifera on LPS-induced nitirc oxide (NO) IL-6 production and TNF-α production in murine macrophages. RAW 264.7 cells were treated with concentrations of hexane fraction (He-AP) and ethyl acetate fraction (EA-AP) in the presence of 500 ng/ml of LPS or LPS alone for 24 h. The production of NO was evaluated by Griess reaction (A) . The concentration of IL-6 (B) and TNF-α (C) in condition medium was analyzed by ELISA. Three independent assays were performed in triplicate and the data shown are the mean ± S.D. *P< 0.05 vs. media alone and #P < 0.05 vs. LPS-treated group (control) ; significance of difference between treated groups by Students-t tests (*) and ANOVA followed by Dunnett’s test (#) .
Abreu,
Innate immunity and toll-like receptors: clinical implications of basic science research.
2004, Pubmed
Abreu,
Innate immunity and toll-like receptors: clinical implications of basic science research.
2004,
Pubmed
Albert,
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase.
2002,
Pubmed
Boscá,
Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate.
2005,
Pubmed
Choi,
Characterization of antimicrobial agents extracted from Asterina pectinifera.
1999,
Pubmed
,
Echinobase
Coker,
Pulmonary fibrosis: cytokines in the balance.
1998,
Pubmed
de las Heras,
Effects of six diterpenes on macrophage eicosanoid biosynthesis.
2001,
Pubmed
Evans,
Nitric oxide: what role does it play in inflammation and tissue destruction?
1995,
Pubmed
Feldmann,
Rheumatoid arthritis.
1996,
Pubmed
Fichtner-Feigl,
Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.
2005,
Pubmed
Ishiguro,
Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis.
1999,
Pubmed
Jung,
Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine-induced cytotoxicity in HepG2 cells.
2004,
Pubmed
Klotz,
Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
2005,
Pubmed
Penglis,
Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors.
2000,
Pubmed
Prendergast,
Invertebrate protein simulating mediators of delayed hypersensitivity.
1970,
Pubmed
Prokof'eva,
Biological activities of steroid glycosides from starfish.
2003,
Pubmed
,
Echinobase
Ruggieri,
Drugs from the sea.
1976,
Pubmed
Sakagami,
The endotoxin of Helicobacter pylori is a modulator of host-dependent gastritis.
1997,
Pubmed
Sautebin,
Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy.
2000,
Pubmed
Sobota,
Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family.
2000,
Pubmed
Sosa,
Screening of the topical anti-inflammatory activity of some Central American plants.
2002,
Pubmed
Tergaonkar,
NFkappaB pathway: a good signaling paradigm and therapeutic target.
2006,
Pubmed
Vane,
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.
1994,
Pubmed
Vernooy,
Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology.
2002,
Pubmed
Walsh,
Rheumatic diseases: the effects of inflammation on bone.
2005,
Pubmed
